Anixa Biosciences, Inc. (ANIX)
NASDAQ: ANIX · Real-Time Price · USD
3.605
-0.055 (-1.50%)
At close: Aug 26, 2026, 4:00 PM EDT
3.600
-0.005 (-0.14%)
Pre-market: Aug 27, 2026, 6:46 AM EDT
Anixa Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
4
Market Cap
122.65M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Oct 31, 2025 | - | - | - |
| Oct 31, 2024 | - | - | - |
| Oct 31, 2023 | 210.00K | - | - |
| Oct 31, 2022 | - | - | - |
| Oct 31, 2021 | 512.00K | - | - |
| Oct 31, 2020 | - | - | - |
| Oct 31, 2019 | 250.00K | -862.50K | -77.53% |
| Oct 31, 2018 | 1.11M | 750.00K | 206.90% |
| Oct 31, 2017 | 362.50K | 62.50K | 20.83% |
| Oct 31, 2016 | 300.00K | -8.96M | -96.76% |
| Oct 31, 2015 | 9.26M | 5.59M | 152.36% |
| Oct 31, 2014 | 3.67M | 3.28M | 843.12% |
| Oct 31, 2013 | 388.85K | -551.16K | -58.63% |
| Oct 31, 2012 | 940.01K | -63.18K | -6.30% |
| Oct 31, 2011 | 1.00M | 272.52K | 37.30% |
| Oct 31, 2010 | 730.68K | -325.12K | -30.79% |
| Oct 31, 2009 | 1.06M | -1.01M | -48.83% |
| Oct 31, 2008 | 2.06M | 1.58M | 323.77% |
| Oct 31, 2007 | 486.85K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Black Diamond Therapeutics | 70.00M |
| Coya Therapeutics | 8.02M |
| Rani Therapeutics Holdings | 4.88M |
| Cibus | 4.35M |
| Inovio Pharmaceuticals | 65.34K |
| NeOnc Technologies Holdings | 39.99K |
| Genelux | 8.00K |
| Fractyl Health | 3.00K |
ANIX News
- 2 days ago - Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy - PRNewsWire
- 8 days ago - Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference - PRNewsWire
- 6 weeks ago - Anixa Biosciences granted Australian patent for breast cancer vaccine - TheFly
- 6 weeks ago - Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology - PRNewsWire
- 7 weeks ago - Anixa Biosciences, Moffitt Cancer advance ovarian cancer CAR-T trial - TheFly
- 7 weeks ago - Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date - PRNewsWire
- 2 months ago - Anixa Biosciences assumed with a Buy at D. Boral Capital - TheFly
- 2 months ago - Anixa Biosciences granted first Korean patent for breast cancer vaccine - TheFly